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Postincarceration Fatal Overdoses After Implementing
Medications for Addiction Treatment in a Statewide
Correctional System
As the epidemic of opioid use in the United States continues
to shift from prescription opioids to illicit drugs,1 more people
living with opioid use disorder are encountering the criminal
justice system. Most US correctional facilities do not con-
tinue or initiate medications for addiction treatment (MAT).2
This is especially unfortunate given the higher rates of opioid
overdose immediately after release from incarceration.3
In July 2016, a new model of screening and protocoled treat-
ment with MAT (including methadone, buprenorphine, or nal-
trexone)launchedattheRhodeIslandDepartmentofCorrections
(RIDOC), a unified prison/jail. A community vendor with state-
wide capacity to provide MAT after release was engaged to help
run the program in November 2016, and all sites were operational
by January 2017. Individuals arriving into RIDOC while receiving
MAT were to be maintained on their respective medications regi-
men without tapering or discontinuing their medications. Con-
temporaneously, a system of 12 community-located Centers of
Excellence in MAT was established to promote transitions and
referrals of inmates released from RIDOC. This analysis examines
preliminary association of the program with overall overdose
fatalities and deaths from overdose among those individuals
who were recently incarcerated.
Methods | We conducted a retrospective cohort analysis linking
data from the Rhode Island Office of State Medical Examiners
for all unintentional deaths from overdose occurring from Janu-
ary 1 to June 30, 2016, and from January 1 to June 30, 2017, to
data from RIDOC inmate releases. Decedents were defined as
individuals who were recently incarcerated if they died within
12 months of release from RIDOC. Descriptive statistics of de-
cedents include summarized demographics, the status of in-
carceration, and the number of fentanyl-related overdoses.
Aggregate data of inmates released from RIDOC, counts of nal-
oxone provided to inmates after release, and the monthly re-
ceipt of MAT were also reported. Risk ratios (RRs) and 95% CIs
were used to compare the proportion of decedents who were
recently incarcerated in 2017 with those who were incarcerated
in 2016, since individual-level MAT program enrollment data
were unavailable. The number needed to treat was estimated
from the risk difference of recent incarceration between the 2
periods. χ2 Tests compared differences in decedent character-
istics between 2016 and 2017. Statistical analysis was performed
using SAS program, version 9.3 (SAS Institute Inc) with 2-sided
P < .05 considered statistically significant. The Rhode Island
Hospital institutional review board approved this protocol with
a waiver of written informed consent.
Results | Statewide in Rhode Island, there were 179 overdose
deaths from January 1, 2016, to June 30, 2016, compared with
157 overdose deaths during the same period in 2017, a reduc-
Table 1. Characteristics and Number of Deaths From Accidental Overdose in Rhode Island,
Both Overall and Among Individuals With Recent Incarcerationa
Characteristic
Decedents With Recent Incarceration,
No. (%) Overall No. of Decedents (%)
First 6 mo of 2016
(n = 26)
First 6 mo of 2017
(n = 9)
First 6 mo of 2016
(n = 179)
First 6 mo of 2017
(n = 157)
Sex
Male 24 (92.3) 7 (77.8) 123 (68.7) 94 (59.9)
Female 2 (7.7) 2 (22.2) 56 (31.3) 63 (40.1)
Race/ethnicityb
White 25 (96.2) 8 (88.9) 168 (93.9) 137 (87.3)c
Other 1 (3.8) 1 (11.1) 11 (6.1) 20 (12.7)
Age, y
18-29 8 (30.8) 2 (22.2) 43 (24.0) 23 (14.6)d
30-39 9 (34.6) 4 (44.4) 34 (19.0) 54 (34.4)
40-49 6 (23.1) 3 (33.3) 40 (22.3) 35 (22.3)
≥50 3 (11.5) 0 (0.0) 62 (34.6) 45 (28.7)
Died of overdose
attributed to fentanyl
16 (61.5) 8 (88.9) 92 (51.4) 92 (58.6)
Length of incarceration,
median (IQR), mo
30 (4-70) 23 (9-113) NA NA
Time since release from
incarceration to death,
median (IQR), d
112 (12-223) 190 (49-241) NA NA
Died within 30 d of release
from incarceration
10 (38.5) 1 (11.1) NA NA
Abbreviations: IQR, interquartile
range; NA, not applicable.
a Recent incarceration was defined as
within 12 months of release from
the Rhode Island Department of
Corrections.
b Race as recorded by the Rhode
Island Office of State Medical
Examiners at the time of autopsy or
case review.
c χ2 Test comparing all decedents,
January 1 to June 30, 2016, vs
January 1 to June 30, 2017, P = .04.
d χ2 Test comparing all decedents,
January 1 to June 30, 2016, vs
January 1 to June 30, 2017, P = .007.
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tion of 12.3%. Characteristics of decedents included in the 2017
group were generally comparable with those of decedents in
2016, but the 2017 group was slightly older and less likely to be
of white race/ethnicity (Table 1). Most deaths from overdose were
fentanyl-related. For decedents who were recently incarcer-
ated, there were no statistically significant differences in char-
acteristics of those decedents in 2016 vs 2017. The total num-
ber of admissions and releases from incarceration were similar
over time; however, the provision of naloxone to inmates after
release from incarceration declined, and the monthly receipt of
MAT after release from incarceration increased (Table 2).
In the 2016 period, 26 of 179 individuals (14.5%) who died
of an overdose were recently incarcerated compared with 9 of
157 individuals (5.7%) in the 2017 period, representing a 60.5%
reduction in mortality (RR, 0.4; 95% CI, 18.4%-80.9%; P = .01).
The number needed to treat to prevent a death from over-
dose was 11 (95% CI, 7-43).
Discussion | We observed a large and clinically meaningful
reduction in postincarceration deaths from overdose among
inmates released from incarceration after implementation of
a comprehensive MAT program in a statewide correctional fa-
cility—a reduction contributing to overall population-level
declines in overdose deaths. Results are consistent with other
studies of the provision of MAT during incarceration,4 yet it
is remarkable that the reduction in mortality occurred in the
face of a devastating, illicit, fentanyl-driven overdose
epidemic.5,6 Alternative explanations for the observed reduc-
tions (eg, differences in population or the provision of nalox-
one) linked to recent incarceration are unsupported.
Limitations of this study include a small sample size, a lack
of MAT data after inmate release, and possible misclassifica-
tion of program exposure (eg, refusal of MAT, denial of opioid
use disorder, and staggered MAT program implementation),
which may have underestimated the association. Additional
individual-level and longitudinal analyses are warranted.
Identification and treatment of opioid use disorder in crimi-
nal justice settings with a linkage to medication and support-
ive care after release from incarceration is a promising strat-
egy to rapidly address the high rates of overdose and opioid
use disorder in the community.
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Table 2. Characteristics of Individuals Incarcerated in Rhode Island
From January 1 to June 30, 2016, and From January 1 to June 30, 2017
Characteristic First 6 mo of 2016 First 6 mo of 2017
Admission for incarceration, No. 4822 4512
Release from incarceration, No. 4005 3426
No. of inmates receiving
MAT monthly, mean (SD)
80 (18)a 303 (39)
No. of inmates receiving a specific
MAT drug monthly, mean (SD)
Buprenorphine 4 (3) 119 (15)
Methadone 74 (16) 180 (25)
Naltrexone 2 (1) 4 (1)
Naloxone kits dispensed at release
from incarceration, No.
72 35
Abbreviations: MAT, medications for addiction treatment; RIDOC, Rhode Island
Department of Corrections.
a Some medications for treatment of addiction were in use at RIDOC in
specialized circumstances. Treatment with an opioid agonist is standard of
care for pregnant women with opioid use disorder. Pregnant women with
opioid use disorder incarcerated at RIDOC are typically treated with
methadone and less frequently with buprenorphine. A pilot study providing
naltrexone by injection had been ongoing since December 2015 prior to the
start of the MAT program at RIDOC.
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COMMENT & RESPONSE
Mendelian Randomization Concerns
To the Editor With interest we read the article by Hartwig et al.1
The authors used 2-sample mendelian randomization2 to in-
vestigate the role of C-reactive protein (CRP) in schizophre-
nia. Their main finding listed in the abstract and body is a
pooled odds ratio estimate of 0.9 (random effects 95% CI,
0.84-0.97; P = .005) per 2-fold increment in CRP levels in their
inverse variance–weighted random-effects model.
First, by comparing the input CRP-associated single-
nucleotide polymorphism (SNP) data from the original CRP
genome-wide study3 (see eTable 2 in the Supplement by
Hartwig et al1), it came to our attention that the effect allele
at rs9987289, the only variant “classified as influential,”1
differs between the studies by Hartwig et al1 and Dehghan
et al.3 We invite the authors to comment on their choosing
the G allele as the effect allele instead of using the data in
Table 2 of Dehghan et al.3
Second, the authors refer to a study by Prins et al4 in which
mendelian randomization analyses were performed using ge-
netic risk scores of liberal CRP-associated SNPs as instrumen-
tal variables also in schizophrenia. These genetic risk scores
are derived from the original CRP study,3 the same data re-
source Hartwig et al1 used. Both groups extracted 18 SNPs.
Prins et al4 did not extract 3 SNPs from Psychiatric Genomics
Consortium schizophrenia summary statistics, resulting in
15 SNPs for their actual analyses. Aiming to elucidate the true
effect size for CRP-associated SNPs in risk for schizophrenia,
we tried to replicate both articles’ findings. To that end, we
applied our own scripts (https://github.com/Bochao1
/MR_CRP_SCZ) and the R packages TwoSampleMR and
MendelianRandomlization to perform the same inverse
variance–weighted random-effects model as used by Hartwig
et al1 for their main finding, as well as 3 of their 4 other models.
To get odds ratio estimates for schizophrenia per 2-fold CRP
increments, we used the same equation1 as follows:
(√OR)2e
However, neither when considering G at rs9987289 as the
effect allele nor when considering A as the effect allele did we
obtain equal inverse variance–weighted random-effects
results to Hartwig et al1 (odds ratio, 0.90 per 2-fold CRP incre-
ment; 95% CI, 0.85-0.96; P=.001; and odds ratio, 0.93; 95%
CI, 0.86-0.99; P=.030, respectively).5
Our findings hint that the actual effect size for CRP-
associated SNPs to increase risk of schizophrenia may differ
from the findings of Hartwig et al.1 To improve future replica-
tion opportunities, we propose that authors refer to publicly
accessible statistical analysis codes (eg, https://github.com/)
and R packages and outline their data extraction procedures.
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In Reply The comments by Lin et al on our mendelian random-
ization analysis of the association of circulating C-reactive
protein (CRP) with schizophrenia risk1 indicate their concern
over the proper extraction and harmonization of data within
2-sample mendelian randomization studies. We agree that this
is an important topic2 that is vital for ensuring the reproduc-
ibility and reliability of scientific findings, and we appreciate
the opportunity to provide some clarifications.
Specifically, they questioned why we considered the G
allele, rather than the A allele, as the effect allele for the
rs9987289 variant (one of the CRP instruments). It is true that
the A allele was indicated as the effect allele in Table 2 of the
study by Dehghan et al,3 which shows summary association
results for the replication and discovery plus replication stages.
Table 1 in the study by Dehghan et al3 indicates that the
G allele was the effect allele in the discovery stage. They reported
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